Tracers / [177Lu]Lu-J591

[177Lu]Lu-J591

Also written as Lu-177-J591; [Lu-177]Lu-J591
Radionuclide
Lu-177 t½ 9584.6 min
Modality
Therapy
Production route
—
Stage
investigational
Syntheses indexed
3
Prostate cancerDosimetry and biodistribution studiesPSMA-directed radioligand therapy

What it is

Compound class
Anti-PSMA monoclonal antibody (J591)
Target / mechanism
Targets prostate-specific membrane antigen (PSMA) PMID 33778927
Clinical application
PSMA-targeted radionuclide therapy in metastatic castration-resistant prostate cancer PMID 33778927
Theranostic pair
—

Regulatory status

FDA
—
EMA (centralised)
—
Other approvals
—
Brand names
—

Clinical use

Typical injected activity
—
Uptake time
—

Reported in the literature. Not a dosing recommendation.

Published syntheses

ModuleCassettePurificationYield %RCP %Precursor / supplierSource
——————38960712
2024 J Nucl Med
—————J59133778927
2021 Curr Oncol Rep
——————33465252
2021 Prostate

Need this precursor?We can point you to suppliers for [177Lu]Lu-J591, or handle the enquiry for you.

Get in touch

Notes

Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 3 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 33778927: 'escalating doses of 177Lu-J591'. Stage set/updated at stage 23 from PMID 33778927: 'Prostate-specific membrane antigen (PSMA)-targeted radionuclide therapy (TRT) is a promising investigational treatment for metastatic castration-resistant prostate cancer (mCRPC).'.